Dohj LLC Buys 739 Shares of Align Technology, Inc. (NASDAQ:ALGN)

Dohj LLC grew its stake in Align Technology, Inc. (NASDAQ:ALGN) by 84.7% during the fourth quarter, Holdings Channel reports. The firm owned 1,611 shares of the medical equipment provider’s stock after purchasing an additional 739 shares during the period. Dohj LLC’s holdings in Align Technology were worth $441,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Rhenman & Partners Asset Management AB bought a new stake in Align Technology during the third quarter worth $305,000. Ameriprise Financial Inc. raised its stake in shares of Align Technology by 348.9% in the third quarter. Ameriprise Financial Inc. now owns 756,393 shares of the medical equipment provider’s stock valued at $230,938,000 after buying an additional 587,886 shares during the period. Invesco Ltd. raised its stake in shares of Align Technology by 15.4% in the third quarter. Invesco Ltd. now owns 960,271 shares of the medical equipment provider’s stock valued at $293,190,000 after buying an additional 128,273 shares during the period. Quadrature Capital Ltd bought a new stake in shares of Align Technology in the third quarter valued at $35,499,000. Finally, DAVENPORT & Co LLC raised its stake in shares of Align Technology by 5,179.5% in the fourth quarter. DAVENPORT & Co LLC now owns 114,671 shares of the medical equipment provider’s stock valued at $31,576,000 after buying an additional 112,499 shares during the period. Institutional investors own 88.43% of the company’s stock.

Insider Activity

In other Align Technology news, Director Joseph Lacob sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $303.22, for a total transaction of $4,548,300.00. Following the completion of the transaction, the director now owns 131,994 shares of the company’s stock, valued at approximately $40,023,220.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Align Technology news, EVP Emory Wright sold 2,524 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total transaction of $725,523.80. Following the transaction, the executive vice president now owns 709 shares in the company, valued at approximately $203,802.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph Lacob sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $303.22, for a total value of $4,548,300.00. Following the transaction, the director now owns 131,994 shares in the company, valued at approximately $40,023,220.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,524 shares of company stock valued at $8,403,924. Insiders own 0.64% of the company’s stock.

Align Technology Stock Down 0.5 %

Shares of NASDAQ ALGN traded down $1.48 during midday trading on Friday, reaching $309.02. The company had a trading volume of 737,294 shares, compared to its average volume of 636,306. Align Technology, Inc. has a one year low of $176.34 and a one year high of $413.20. The firm’s fifty day moving average price is $313.38 and its 200-day moving average price is $270.98. The stock has a market cap of $23.25 billion, a PE ratio of 50.91, a price-to-earnings-growth ratio of 5.56 and a beta of 1.65.

Align Technology (NASDAQ:ALGN) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.13. Align Technology had a return on equity of 14.15% and a net margin of 11.80%. The company had revenue of $956.73 million during the quarter, compared to analyst estimates of $928.57 million. As a group, equities research analysts expect that Align Technology, Inc. will post 7.69 EPS for the current year.

Wall Street Analyst Weigh In

ALGN has been the topic of several research reports. The Goldman Sachs Group boosted their target price on Align Technology from $197.00 to $225.00 and gave the company a “sell” rating in a research note on Friday, February 2nd. SVB Leerink began coverage on Align Technology in a research report on Monday, February 26th. They issued a “market perform” rating and a $310.00 price target for the company. Robert W. Baird lifted their price target on Align Technology from $333.00 to $370.00 and gave the company an “outperform” rating in a research report on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $375.00 price target (up from $355.00) on shares of Align Technology in a research report on Thursday. Finally, Morgan Stanley boosted their target price on Align Technology from $344.00 to $360.00 and gave the stock an “overweight” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $341.36.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.